Follow the company. Check the evidence.
Public records connected to stocks traded by Congress. See what changed, when it became public, and the original source.
MDGL: BAKER BROS. ADVISORS LP; Baker Bros. Advisors (GP) LLC; BAKER FELIX; BAKER JULIAN; 667, L.P.; Baker Brothers Life Sciences LP reported buying shares
5 reported purchases of non-derivative securities. Code P includes open-market and private purchases; it does not establish motive.
MDGL: third_quarter 2026 lobbying report
FDA and regulatory issues related to the biopharmaceutical industry. FDA and regulatory issues related to the biopharmaceutical industry. FDA and regulatory issues related to the biopharmaceutical industry, including CMMI Drug Pricing Models.
Public: Oct 20, 2026, 3:55 PM EDTOriginal source ↗MDGL: third_quarter 2026 lobbying report
Issues related to CMMI drug pricing; 340B drug pricing Most Favored Nation drug pricing; Issues related to CMMI drug pricing
Public: Oct 19, 2026, 3:46 PM EDTOriginal source ↗MDGL: third_quarter 2026 lobbying report
Issues related to drug pricing; Delivering Most-Favored-Nation Prescription Drug Pricing to American Patients Executive Order; Section 301 tariffs. Issues related to CMMI Drug Pricing Demonstration Programs (GLOBE and GUARD Models); GENEROUS Medicaid Drug Pricing Model.
Public: Oct 19, 2026, 11:29 AM EDTOriginal source ↗MDGL: third_quarter 2026 lobbying report
Advocacy related to prescription drug access and pricing.
Public: Oct 18, 2026, 2:08 PM EDTOriginal source ↗MDGL: second_quarter 2026 lobbying report
Issues related to CMMI drug pricing; 340B drug pricing Most Favored Nation drug pricing; Issues related to CMMI drug pricing
Public: Jul 20, 2026, 4:10 PM EDTOriginal source ↗MDGL: second_quarter 2026 lobbying report
Issues related to CMMI Drug Pricing Demonstration Programs (GLOBE and GUARD Models). Issues related to drug pricing; Delivering Most-Favored-Nation Prescription Drug Pricing to American Patients Executive Order; Section 301 tariffs.
Public: Jul 19, 2026, 9:22 PM EDTOriginal source ↗MDGL: second_quarter 2026 lobbying report
FDA and regulatory issues related to the biopharmaceutical industry. FDA and regulatory issues related to the biopharmaceutical industry. FDA and regulatory issues related to the biopharmaceutical industry, including CMMI Drug Pricing Models.
Public: Jul 16, 2026, 4:25 PM EDTOriginal source ↗MDGL: second_quarter 2026 lobbying report
Advocacy related to prescription drug access and pricing.
Public: Jul 15, 2026, 7:02 PM EDTOriginal source ↗
Connections describe public records, not evidence of wrongdoing or a prediction of returns. Event dates can precede publication by days or months. When a source has no public-release timestamp, we show when we first observed it.
Source coverage
Coverage is growing across companies already tracked here. A scan can return no matching records. This feed is not a complete record of every filing or agency action.
- SEC EDGAR
- Current across tracked companies505 of 505 companies scanned in the past 12 hoursLatest successful company scan: Nov 12, 2026, 2:06 PM EST
- USAspending
- Collection in progress76 of 548 companies scanned in the past 12 hoursLatest successful company scan: Nov 12, 2026, 2:06 PM EST
- SAM.gov
- Awaiting company connections
- Lobbying disclosures
- Not yet scanned0 of 548 companies scanned in the past 12 hours
- Congress.gov
- Current across tracked companies5 of 5 companies scanned in the past 12 hoursLatest successful company scan: Nov 12, 2026, 12:27 PM EST
- Federal Register
- Stale — refresh overdue297 of 548 companies scanned in the past 12 hoursLatest successful company scan: Nov 12, 2026, 2:06 PM EST
- Regulations.gov
- Partial coverage — some requests unavailable31 of 53 companies scanned in the past 12 hoursLatest successful company scan: Nov 12, 2026, 2:00 PM EST
- FEC campaign finance
- Stale — refresh overdue0 of 548 companies scanned in the past 12 hoursLatest successful company scan: Nov 11, 2026, 1:28 PM EST